OTC Markets OTCPK - Delayed Quote USD

Tsumura & Co. (TSMRF)

28.15
0.00
(0.00%)
At close: May 21 at 4:00:00 PM EDT
Loading Chart for TSMRF
  • Previous Close 0.00
  • Open 28.15
  • Bid 22.95 x 40000
  • Ask 26.05 x 40000
  • Day's Range 28.15 - 28.15
  • 52 Week Range 26.76 - 28.15
  • Volume 100
  • Avg. Volume 0
  • Market Cap (intraday) 2.369B
  • Beta (5Y Monthly) 0.03
  • PE Ratio (TTM) 13.03
  • EPS (TTM) 2.16
  • Earnings Date Aug 4, 2025 - Aug 8, 2025
  • Forward Dividend & Yield 0.88 (3.11%)
  • Ex-Dividend Date Sep 29, 2025
  • 1y Target Est --

Tsumura & Co. manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally. The company offers Kampo extract intermediates, granular and prescription Kampo formulations, over-the-counter Kampo medicine, other medications, and herbal bath salts. It offers its products for female problems, proneness to fatigue, skin problems, gastrointestinal problems, obesity, constipation, hemorrhoid, body aches, cold, cough, nasal/throat inflammation, children's sickness, stress, and urinary problems. Tsumura & Co. was founded in 1893 and is headquartered in Tokyo, Japan.

www.tsumura.co.jp

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: TSMRF

View More

Performance Overview: TSMRF

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

TSMRF
170.64%
Nikkei 225 (^N225)
7.29%

1-Year Return

TSMRF
47.51%
Nikkei 225 (^N225)
4.22%

3-Year Return

TSMRF
1,001.69%
Nikkei 225 (^N225)
38.32%

5-Year Return

TSMRF
1,468,438.90%
Nikkei 225 (^N225)
81.41%

Compare To: TSMRF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TSMRF

View More

Valuation Measures

Annual
As of 12/18/2024
  • Market Cap

    1.84B

  • Enterprise Value

    1.82B

  • Trailing P/E

    13.02

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.99

  • Price/Book (mrq)

    1.12

  • Enterprise Value/Revenue

    2.14

  • Enterprise Value/EBITDA

    7.38

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.91%

  • Return on Assets (ttm)

    5.62%

  • Return on Equity (ttm)

    11.04%

  • Revenue (ttm)

    181.09B

  • Net Income Avi to Common (ttm)

    32.43B

  • Diluted EPS (ttm)

    2.16

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    73.23B

  • Total Debt/Equity (mrq)

    21.31%

  • Levered Free Cash Flow (ttm)

    251M

Research Analysis: TSMRF

View More

Company Insights: TSMRF

Research Reports: TSMRF

View More

People Also Watch